Genetically predicted inhibition of PCSK9 was associated with lower risk of CAD but not T2D, and genetically predicted inhibition of HMGCR was associated with lower risk of CAD, but higher risk of T2D (Figure 2B). Here, HMGCR is linked to type 2 diabetes mellitus.